Regeneron Pharmaceuticals (REGN) Free Cash Flow (2009 - 2026)

Regeneron Pharmaceuticals has reported Free Cash Flow for 18 years, with the latest figure at $848.3 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 3.98% year-over-year to $848.3 million; the trailing twelve-month figure through Mar 2026 stood at $4.1 billion (up 32.6% YoY), and the FY2025 full-year result was $4.1 billion, up 11.35% from the prior year.
• Free Cash Flow for Q1 2026 stood at $848.3 million, down from $922.0 million in the prior quarter.
• The five-year high for Free Cash Flow was $2.0 billion in Q1 2022, with the low at $336.3 million in Q2 2024.
• Average Free Cash Flow over 5 years is $993.7 million, with a median of $922.0 million recorded in 2025.
• Year-over-year, Free Cash Flow slumped 85.17% in 2022 and soared 255.31% in 2025.
• Tracing REGN's Free Cash Flow over 5 years: stood at $1.6 billion in 2022, then sank by 46.53% to $838.3 million in 2023, then grew by 26.83% to $1.1 billion in 2024, then retreated by 13.28% to $922.0 million in 2025, then fell by 7.99% to $848.3 million in 2026.
• The last three Free Cash Flow figures came in at $848.3 million (Q1 2026), $922.0 million (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.

Peer Comparison